Recombinant Fusion Proteins

"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.

Descriptor ID	D011993
MeSH Number(s)	D12.776.828.300
Concept/Terms	Recombinant Fusion Proteins Recombinant Fusion Proteins Proteins, Recombinant Fusion Fusion Proteins, Recombinant Hybrid Proteins, Recombinant Hybrid Proteins, Recombinant Proteins, Recombinant Hybrid Recombinant Hybrid Proteins Chimeric Proteins, Recombinant Chimeric Proteins, Recombinant Proteins, Recombinant Chimeric Recombinant Chimeric Proteins

Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Recombinant Proteins [D12.776.828]
Recombinant Fusion Proteins [D12.776.828.300]

Below are MeSH descriptors whose meaning is related to "Recombinant Fusion Proteins".

Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".

Recombinant Fusion Proteins
CD4 Immunoadhesins
Transcription Activator-Like Effector Nucleases
Zinc Finger Nucleases

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.

Bar chart showing 292 publications over 29 distinct years, with a maximum of 30 publications in 2002

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	6	6
1996	0	2	2
1997	0	3	3
1998	0	2	2
1999	0	7	7
2000	0	8	8
2001	2	9	11
2002	2	28	30
2003	3	10	13
2004	2	22	24
2005	3	20	23
2006	2	16	18
2007	3	18	21
2008	0	4	4
2009	6	14	20
2010	3	9	12
2011	3	6	9
2012	7	5	12
2013	8	0	8
2014	4	2	6
2015	10	6	16
2016	3	3	6
2017	3	3	6
2018	3	3	6
2019	3	5	8
2020	1	1	2
2021	2	2	4
2022	0	4	4
2024	0	1	1

Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.

Hayashi M, Girdhar A, Ko YH, Kim KM, DePierro JA, Buchler JR, Arunprakash N, Bajaj A, Cingolani G, Guo L. Engineered NLS-chimera downregulates expression of aggregation-prone endogenous FUS. Nat Commun. 2024 Sep 10; 15(1):7887.

View in: PubMed
Sharma A, Parachuri N, Kumar N, Kuppermann BD, Bandello F, Regillo CD. The port delivery system with ranibizumab: understanding nuances for clinical use in the real world. Expert Opin Biol Ther. 2022 06; 22(6):675-677.

View in: PubMed
Regillo C, Singh R, Hamilton R, Gedif K, Best C, Koh A, Holz FG. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials. Ophthalmologica. 2022; 245(5):403-412.

View in: PubMed
Salabati M, Obeid A, Mahmoudzadeh R, Gupta O, Chiang A, Spirn M, Klufas MA, Hsu J. Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2022 Aug; 260(8):2509-2516.

View in: PubMed
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 02 19; 399(10326):729-740.

View in: PubMed
Nanji K, Sarohia GS, Kennedy K, Ceyhan T, McKechnie T, Phillips M, Devji T, Thabane L, Kaiser P, Sarraf D, Garg SJ, Sivaprasad S, Wykoff CC, Bakri SJ, Sheidow T, Bhandari M, Chaudhary V. The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure: A Network Meta-Analysis. Ophthalmology. 2022 05; 129(5):498-508.

View in: PubMed
Hinkle JW, Hsu J. THE RELATIONSHIP BETWEEN STOPPER POSITION AND INJECTION VOLUME IN RANIBIZUMAB AND AFLIBERCEPT PREFILLED SYRINGES. Retina. 2021 Dec 01; 41(12):2510-2514.

View in: PubMed
Aslanis S, Amr?n U, Lindberg C, Epstein D. Recurrent Neovascular Age-Related Macular Degeneration after Discontinuation of Vascular Endothelial Growth Factor Inhibitors Managed in a Treat-and-Extend Regimen. Ophthalmol Retina. 2022 01; 6(1):15-20.

View in: PubMed
Obeid A, Hsu J, Ehmann D, Gao X, Sridhar J, Chiang A, Park CH, Ho AC. TOPICAL DORZOLAMIDE-TIMOLOL WITH INTRAVITREOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL VEIN OCCLUSION: A PILOT STUDY. Retin Cases Brief Rep. 2021 Mar 01; 15(2):120-126.

View in: PubMed
Mellen PL, Obeid A, Wibbelsman TD, Hsu J, Konkoly MA, Velez MR, Calem DB, Sioufi K, Jenkins TL, Xu D, Chiang A, Gupta OP, Spirn M, Regillo CD, Ho AC, Klufas MA. Clinical Outcomes of Eyes With Diabetic Macular Edema Switched From Aflibercept to Ranibizumab Therapy. Ophthalmic Surg Lasers Imaging Retina. 2020 12 01; 51(12):691-697.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement